Reuters -- The U.S. Food and Drug Administration has asked Bayer AG (BAYGn.DE), Amylin Pharmaceuticals (AMLN.O), Eli Lilly (LLY.N) and Cephalon (CEPH.O) to stop using “misleading” promotions for some drugs, according to letters released by the agency on Tuesday.
